Syngene receives USFDA clearance; legal head resigns
Syngene International (BSE: SYNGENE) announced that it has received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its GMP manufacturing facilities located at Biocon Park, Bengaluru, following an inspection conducted between February 10 and February 20, 2025. The USFDA classified the inspectional outcome as Voluntary Action Indicated (VAI), indicating that the FDA has reviewed and accepted Syngene’s corrective action plans submitted in response to the inspection findings.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
News Alerts
Get instant email alerts when Syngene International publishes news
Free account required • Unsubscribe anytime